KZR Company Profile and Key Details

KZR has shown mixed momentum, gaining 0.16% over the past week and -3.3% over the past quarter, though year-to-date performance is down -2.23%. Short-term trend indicators are bearishly aligned (SMA20 5.21%, SMA50 6.32%, SMA200 31.31%). The stock’s 14-day RSI is 66.86 (firm momentum), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -2.33% below its high and over 89.62% above its low.

Kezar Life Sciences, Inc. has 7.32 million shares outstanding. The public float is 4.69 million shares, elevated short interest at 8.23% of float. This equals 588.61 thousand shares. The short ratio is 8.59 days. Institutional investors hold 68.35% of the float. Insiders own 10.57%. Equal Talent Investments Ltd holds 6.25 million shares, Morningside Venture Investments Ltd has 5.45 million shares and Cormorant Asset Management, LP has 1.57 million shares.

The stock is currently within 5% of its 52-week high $3.53 and $7.55. With a market capitalization of about $53.86 million, Kezar Life Sciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.41). Key stats such as the average daily volume over the past year has been around 87.92 thousand shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, Kezar Life Sciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christopher J. Kirk, the company employs approximately 55 people and listed since June 21, 2018. Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies.

Kezar Life Sciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $9.51. This means the shares are trading below this model’s fair value.

Kezar Life Sciences, Inc. generated EPS of -$8.44 over the past year. Five-year average earnings growth is 8.98%. Wall Street analysts project EPS growth of 26.34% annually over the next five years. The latest quarter delivered EPS of -$0.78. The next quarter is forecast at -$1.31. Next year's EPS is expected at $16.12. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $5.00. The high target offers -3.98% upside. The low target suggests -31.41% downside. The mean target is $6.00. This offers -17.7% upside. Kezar Life Sciences, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 11, 2026, missed forecasts by -20.41%. The prior quarter beat by 51.98%. Over the last six quarters, Apple has recorded several small beats. These include -11.33% in May 13, 2025.

Kezar Life Sciences, Inc. trades at a P/E ratio of -1.18, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.82 suggesting the stock is closer to book value. The P/FCF stands at -1.28, also above market averages.

Our AI price prediction model suggests that Kezar Life Sciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.23%, with price expected at $7.20 by May 22, 2026, within a range of $6.94 to $7.47 3-Month Outlook: Projected fall of -47.87%, reaching $3.80 by August 06, 2026, with a range of $2.38 to $4.78. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by May 07, 2027, within a range of $0.00 to $2.99.

Kezar Life Sciences, Inc. (NASDAQ:KZR) shares are flat -2.23% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Kezar Life Sciences, Inc. trading at a premium to the broader market with a P/E of -1.18. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $11.69, suggesting 60.36% upside. Our AI forecast model points to short-term weakness (-1.23% over two weeks), a medium-term fall (-47.87% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.